Technology Overview
OHSU researchers have identified a novel treatment method which, when used in combination with first-line cancer therapies, has the potential to minimize residual disease, the primary cause of relapse in all cancers. The method leverages existing drugs that inhibit a metabolic target molecule not previously understood to be involved in autophagy, a biological mechanism that supports tumor cell survival. Inhibition of this target, combined with standard therapy, can be used to treat cancers more effectively.
Licensing Opportunity
This technology is available for exclusive licensing and/or collaborative co-development.